medRxiv : the preprint server for health sciences · 2025
Early Genetic Evolution of Driver Mutations in Uveal Melanoma.
СтатьяПрепринтНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dollar James J, Decatur Christina L, Weis Ezekiel, Schefler Amy C, Materin Miguel A, Fuller Timothy S, Skalet Alison H, Reichstein David A, Kim Ivana, Piggott Kisha D, Demirci Hakan, Aaberg Thomas A, Mruthyunjaya Prithvi, Williams Basil K, Shildkrot Eugene, Oliver Scott C N, Char Devron H, Capone Antonio, Mason John, Walter Scott D, Altaweel Michael, Wells Jill, Gombos Dan S, Duker Jay, Hovland Peter, Tsai Tony, Javid Cameron, Durante Michael A, Covington Kyle R, Zhang Song, Correa Zelia M, Harbour J William
Аннотация
Uveal melanoma (UM) is an aggressive cancer of the eye that frequently results in metastatic death. UMs are most likely to metastasize when they are small, at a time when they are difficult to distinguish from benign nevi and often observed without treatment. Unfortunately, little is known about the early genetic evolution of UM or potential biomarkers to indicate small tumors undergoing malignant transformation. Here, we performed targeted next generation sequencing for the 7 canonical UM driver mutations in 1140 primary UMs, including 131 small early-stage tumors. We found that the evolutionary burst of genetic aberrations that determines the archetypal UM subtypes and metastatic propensity has already occurred by the time most small tumors are biopsied, although a significantly larger proportion of small tumors are still evolving compared to larger tumors. We found that the 15-gene expression profile (15-GEP) support vector machine discriminant score was the best indicator of tumors in transition from low-risk Class 1 to high-risk Class 2 signature. While BAP1, SF3B1 and EIF1AX mutations were associated with poor, intermediate and good prognosis, respectively, mutation analysis was inferior to the prospectively validated 15-GEP + PRAME expression classifier for predicting metastasis-free and overall survival. These results provide a more complete picture of genetic evolution in UM, and they move us closer to a molecular definition of malignant transformation in this cancer type.